Catalogo dei prodotti della ricerca

MAURO, Francesca Romana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.431
EU - Europa 2.563
AS - Asia 1.561
SA - Sud America 54
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 12.651
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.343
SE - Svezia 723
IT - Italia 674
SG - Singapore 610
IN - India 551
CN - Cina 360
UA - Ucraina 312
FI - Finlandia 276
DE - Germania 174
RO - Romania 133
GB - Regno Unito 91
CA - Canada 84
IE - Irlanda 48
AR - Argentina 40
BG - Bulgaria 35
GR - Grecia 33
TG - Togo 25
FR - Francia 12
BE - Belgio 10
CH - Svizzera 9
HK - Hong Kong 9
JP - Giappone 9
NL - Olanda 9
ZA - Sudafrica 9
BR - Brasile 8
IR - Iran 8
TR - Turchia 7
CL - Cile 6
RS - Serbia 5
RU - Federazione Russa 5
DK - Danimarca 4
ES - Italia 4
MX - Messico 4
EU - Europa 3
AT - Austria 2
AU - Australia 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
CZ - Repubblica Ceca 1
HR - Croazia 1
MA - Marocco 1
MK - Macedonia 1
PH - Filippine 1
PK - Pakistan 1
SC - Seychelles 1
TN - Tunisia 1
VN - Vietnam 1
Totale 12.651
Salva come PNG Salva come JPEG
Città #
Fairfield 1.296
Woodbridge 674
Chandler 575
Houston 525
Ashburn 486
Wilmington 486
Seattle 452
Singapore 410
Ann Arbor 398
Cambridge 391
Princeton 316
Plano 249
Beijing 239
San Paolo di Civitate 237
Boston 232
Rome 199
Lawrence 171
Dearborn 128
Jacksonville 122
San Diego 115
Andover 88
Des Moines 81
Millbury 74
Bremen 62
Santa Clara 60
Toronto 53
Norwalk 51
Dublin 48
Helsinki 44
San Mateo 43
Federal 37
Sofia 35
Southend 35
Stockholm 33
Falls Church 31
Boardman 29
New York 26
Bühl 25
Lomé 25
Hefei 22
Ottawa 22
Mannheim 21
Kunming 19
Milan 17
Nanjing 11
Redmond 11
Auburn Hills 10
Brussels 10
Cagliari 10
Los Angeles 10
Turin 8
Westminster 8
London 7
Muizenberg 7
Naples 7
Buffalo 6
Hong Kong 6
Istanbul 6
Jinan 6
Laurel 6
Nuoro 6
Timisoara 6
Fortaleza 5
Nanchang 5
North York 5
Phoenix 5
Prineville 5
Shenyang 5
Springfield 5
Bern 4
Dallas 4
Fuzhou 4
Gossolengo 4
Guangzhou 4
Indiana 4
Kyoto 4
Moscow 4
Napoli 4
Pisa 4
Pozzuoli 4
Pune 4
Redwood City 4
Sacramento 4
Tehran 4
Walsall 4
Accadia 3
Almora 3
Changsha 3
Crotone 3
Falkenstein 3
Grafing 3
Mexico City 3
Montréal 3
Mumbai 3
Ningbo 3
Oxford 3
Riva 3
Solbiate Arno 3
Wuhan 3
Xi'an 3
Totale 8.967
Salva come PNG Salva come JPEG
Nome #
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. 137
Clinical relevance of silent red blood cell autoantibodies. 112
COMBINATION OF CYTOSINE-ARABINOSIDE (ARA-C), CYCLOPHOSPHAMIDE AND PREDNISONE IN THE TREATMENT OF B-CHRONIC LYMPHOCYTIC-LEUKEMIA IN ADVANCED STAGES AND PROGRESSIVE DISEASE 96
Efficacy and safety of long term tenofovir in high risk patients with hematological malignancies (HM) to prevent Hepatitis B Virus (HBV) reactivation after immunosuppressive therapies in real life 96
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 89
null 86
Adhesion molecule expression on B-cell chronic lymphocytic leukemia cells: malignant cell phenotypes define distinct disease subsets 85
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression 84
Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic features of 9 cases 83
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 83
Clinical characteristics and outcome of patients with autoimmune hemolytic anemia (AIHA) uniformly defined as primary by a diagnostic work-up 83
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features 82
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 82
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. 82
An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients 80
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: Multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials 79
BCR-ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. 79
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. 78
A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. 78
Adhesion molecule expression on B-cells from acute and chronic lymphoid leukemias. 77
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. 77
A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia 77
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. 76
An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0. 76
Angiogenic activity in 1(g)V(H) mutated and unmutated chronic lymphocytic leukemia (CLL): Indications for the therapeutic use of VEGF-signaling inhibitors. 75
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. 75
Hodgkin/Reed-Sternberg cells and Hodgkin's disease in patients with B-cell chronic lymphocytic leukaemia: an immunohistological, molecular and clinical study of four cases suggesting a heterogeneous pathogenetic background 75
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation 75
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. 75
Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. 74
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. 74
IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells 73
Another treatment option for relapsed or refractory chronic lymphocytic leukaemia. 73
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. 72
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. 72
High occurence of DRB1 11 in chronic lymphocytic leukaemia families 71
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib 71
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. 71
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia 71
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 70
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia 69
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL 68
SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia 68
null 68
p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis 68
A SINGLE-ARM MULTI-CENTER TRIAL OF BENDAMUSTINE GIVEN WITH OFATUMUMAB (BENDOFA) IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA. GIMEMA CLL0809 PROTOCOL 68
“Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia” 67
Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient 67
Evaluation of marrow and blood haemopoietic progenitors in chronic lymphocytic leukaemia before and after chemotherapy. 67
Standard conditioning regimen and T-depleted donor bone marrow for transplantation in chronic myeloid leukemia 67
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features 66
Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia 66
Acute leukaemia in patients treated for Hodgkin's disease 66
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy 66
Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors 66
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. 66
Alpha-2b interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation. 65
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. 64
NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment 64
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations 64
null 63
Monocytopenia and infections in chronic lymphocytic leukemia (CLL) 63
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab 63
“Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia” 62
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience 62
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience. 62
Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly 61
IgV(H) germline and mutated chronic lymphocytic leukemia (CLL) cases exert a diverse responsiveness upon BCR ligation. 61
New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia 60
Enteral nutrition may cause false-positive results of Aspergillus Galactomannan assay in absence of gastrointestinal diseases 59
Evidence of a sub-clinical lymphoproliferative disease in patients with 'idiopathic' autoimmune hemolytic anemia 59
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 59
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 59
Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. 58
null 58
Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to the clinical outcome: on behalf of the GIMEMA Chronic Lymphoproliferative Diseases Working Group. 58
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 58
null 56
null 56
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IMMUNOCHEMOTHERAPY AND IBRUTINIB. 56
Gene expression profile reveals a unique pattern of protein kinases in chronic lymphocytic leukemia (CLL) potential role of the second generation protein kinase inhibitors 55
A RETROSPECTIVE MULTICENTER TRIAL WITH LOW-DOSE ALEMTUZUMAB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. ON BEHALF OF THE GIMEMA CHRONIC LYMPHOPROLIFERATIVE DISORDERS WORKING PARTY 55
A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukaemia 54
The microRNA (miR) profile in B-cell chronic lymphocytic leukemia (CLL) reveals a differential expression of miR-21, miR-155 and miR-150 between leukemic and normal B lymphocytes, and of miR-150, miR-29bc and miR-223 between IgV(H) mutated and unmutated patients 54
Chronic lymphocytic leukemia in less fit patients: "slow-go". 54
null 54
Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro. 54
Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients 54
Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia 53
Young patients with Chronic Lymphocytic Leukemia 53
Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405 53
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 53
null 53
null 53
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 53
Gene expression profile of protein kinases reveals a distinctive signature of chronic lymphocytic leukemia (CLL) and points to a role of second generation protein kinase inhibitors. 52
Monoclonal B-cell lymphocytosis: A reappraisal of its clinical implications 52
Distribution of genetic and molecular prognostic markers in young patients with Chronic Lymphocytic Leukemia (CLL) in different phases of the disease. 52
TH2/TH1 shift under Ibrutinib treatment in chronic lymphocytic leukemia 52
Anemia emolitica autoimmune: aspetti sierologici e clinici in 596 pazienti 51
Totale 6.811
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.058
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.058
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.298 0 0 20 124 278 397 348 322 278 271 142 118
2020/2021974 115 151 24 72 80 48 17 142 91 142 73 19
2021/20223.086 52 168 235 299 425 77 52 282 172 234 457 633
2022/20232.532 618 607 108 214 217 307 37 140 195 11 61 17
2023/2024996 54 151 34 69 60 60 26 82 19 158 139 144
2024/2025562 117 295 150 0 0 0 0 0 0 0 0 0
Totale 13.071